10x Genomics (TXG) – Investment Analysts’ Weekly Ratings Updates

A number of firms have modified their ratings and price targets on shares of 10x Genomics (NASDAQ: TXG) recently:

• 9/28/2026 – 10x Genomics had its price target raised by Piper Sandler from $47.00 to $80.00. They now have a “neutral” rating on the stock.
• 9/28/2026 – 10x Genomics is now covered by Argus. They set a “buy” rating and a $110.00 price target on the stock.
• 9/21/2026 – 10x Genomics had its “sell (d-)” rating reaffirmed by Weiss Ratings.
• 9/9/2026 – 10x Genomics is now covered by UBS Group AG. They set a “neutral” rating and a $68.00 price target on the stock.
• 9/1/2026 – 10x Genomics is now covered by Royal Bank Of Canada. They set a “sector perform” rating and a $70.00 price target on the stock.
• 9/1/2026 – 10x Genomics is now covered by Royal Bank Of Canada. They set a “sector perform” rating and a $70.00 price target on the stock.
• 8/12/2026 – 10x Genomics had its price target raised by Stephens from $50.00 to $65.00. They now have an “overweight” rating on the stock.
• 8/10/2026 – 10x Genomics had its price target raised by Piper Sandler from $42.00 to $47.00. They now have a “neutral” rating on the stock.
• 8/10/2026 – 10x Genomics had its price target raised by Canaccord Genuity Group Inc. from $50.00 to $60.00. They now have a “buy” rating on the stock.
• 8/7/2026 – 10x Genomics had its price target raised by Morgan Stanley from $37.00 to $40.00. They now have an “equal weight” rating on the stock.
• 8/7/2026 – 10x Genomics was given a new $50.00 price target by Stifel Nicolaus.
• 8/7/2026 – 10x Genomics had its price target raised by Citigroup Inc. from $45.00 to $50.00. They now have a “neutral” rating on the stock.

Insiders Place Their Bets

In related news, Director John R. Stuelpnagel sold 20,000 shares of 10x Genomics stock in a transaction that occurred on Thursday, September 3rd. The stock was sold at an average price of $61.75, for a total transaction of $1,235,000.00. Following the sale, the director owned 328,436 shares of the company’s stock, valued at approximately $20,280,923. This trade represents a 5.74% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, insider Benjamin J. Hindson sold 13,818 shares of 10x Genomics stock in a transaction that occurred on Monday, August 24th. The shares were sold at an average price of $63.02, for a total value of $870,810.36. Following the sale, the insider directly owned 488,182 shares in the company, valued at $30,765,229.64. This trade represents a 2.75% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Over the last ninety days, insiders sold 179,333 shares of company stock valued at $11,810,070. Insiders own 8.84% of the company’s stock.

10x Genomics, Inc develops life science technology for analyzing biological systems at the single-cell and spatial levels. Its platforms are designed to help researchers study gene expression, genetic variation, cell populations and tissue organization with greater detail than conventional laboratory methods.

The company’s product portfolio includes the Chromium platform for single-cell analysis, Visium solutions for spatial transcriptomics and tissue profiling, and Xenium in situ platforms for high-resolution analysis of RNA and other biological features within tissue samples.